Sun Pharma Advanced Research Company Ltd

SPARC Q3 FY26 Results: Revenue Drops, Losses Narrow Slightly 📊

• Q3 standalone revenue: ₹845 lakhs (down from ₹1,491 lakhs in Q3 2024)

• Nine-month standalone revenue: ₹2,595 lakhs (down from ₹4,458 lakhs prior year)

• Q3 standalone net loss: ₹8,057 lakhs (vs ₹7,971 lakhs loss in Q3 2024)

• Nine-month net loss improved to ₹20,857 lakhs (from ₹28,424 lakhs prior year)

• Received Rare Pediatric Disease Priority Review Voucher from US FDA on February 03, 2026 for Sezaby®

• Exceptional item of ₹1,236 lakhs recognized due to India's New Labour Codes impact

• Basic loss per share: ₹(2.48) for Q3, ₹(6.43) for nine months